Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 7/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 7/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 6/20 | 0.34 |
| ▸ | CDK1 | P06493 | 6/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 6/20 | 0.34 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.34 |
| ▸ | CCNB3 | Q8WWL7 | 6/20 | 0.34 |
| ▸ | GSK3A | P49840 | 6/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17159764 | 0.76 | CCNB2 (0.38) | GSK3BCDK5CCNB2CDK1CCNB1 | |
| SCHEMBL4261079 | 0.76 | GSK3B (0.38) | GSK3BCDK5CCNB2CDK1CCNB1 | |
| SCHEMBL3504133 | 0.74 | PDK2 (0.38) | CDK5CCNB2CDK1CCNB1CDK5R1 | |
| SCHEMBL8723154 | 0.74 | KDM4E (0.42) | ADORA2ACDK5CCNB2CDK1CCNB1 | |
| Pterine SCHEMBL64321 | 0.72 | ALDH1A1 (0.41) | GSK3BCDK5CCNB2CDK1CCNB1 | |
| SCHEMBL3817890 | 0.72 | PARP1 (0.49) | ADORA2ACDK1KDM4EALDH1A1LMNA | |
| SCHEMBL28569682 | 0.72 | CCNB2 (0.40) | GSK3BCDK5CCNB2CDK1CCNB1 | |
| SCHEMBL1622735 | 0.72 | AURKA (0.51) | ADORA2ACDK5CDK5R1ALDH1A1MAPT | |
| Pterine SCHEMBL702492 | 0.71 | ALDH1A1 (0.40) | GSK3BCDK5CCNB2CDK1CCNB1 | |
| Pterine SCHEMBL5703599 | 0.71 | ALDH1A1 (0.40) | GSK3BCDK5CCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150336927-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2015-11-26 | — | — | US | disclosed |
| US-9045453-B2 | Substituted dioxopiperidinyl phthalimide derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| WO-2014110322-A2 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-07-17 | — | — | WO | disclosed |
| EP-2373165-B1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIES | CONCERT PHARMACEUTICALS INC (US) | 2013-10-30 | — | — | EP | disclosed |
| WO-2013130849-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130150408-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012079022-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012079075-A1 | DEUTERATED PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | WO | disclosed |
| WO-2012015986-A2 | SUBSTITUTED DIOXOPIPERIDINYL PHTALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2012-02-02 | — | — | WO | disclosed |
| US-20110288126-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| EP-2373165-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIES | CONCERT PHARMACEUTICALS, INC. (US) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010056344-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIES | CONCERT PHARMACEUTICALS INC. (US) | 2010-05-20 | — | — | WO | disclosed |
| EP-0759927-B1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | US GOV HEALTH & HUMAN SERV (US) | 1998-06-24 | — | — | EP | disclosed |
| US-5612468-A | GENETIC ENGINEERING | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-18 | — | — | US | disclosed |
| EP-0759927-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-05 | — | — | EP | disclosed |
| US-5525711-A | MONOMERS FOR DNA AMPLIFICATION PROCEDURES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-06-11 | — | — | US | disclosed |
| WO-1995031469-A1 | PTERIDINE NUCLEOTIDE ANALOGS AS FLUORESCENT DNA PROBES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110288126-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | NFATC1, PDCD11, IL5 | ADORA2A 2800/4885GSK3B 2236/4885CDK5 3176/4885 |
| US-20130150408-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | NFATC1, PDCD11, IL5 | ADORA2A 2800/4885GSK3B 2236/4885CDK5 3176/4885 |
| US-20150336927-A1 | SUBSTITUTED DIOXOPIPERIDINYL PHTHALIMIDE DERIVATIVES | NFATC1, PDCD11, IL5 | ADORA2A 2800/4885GSK3B 2236/4885CDK5 3176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.